Development of patient derived xenograft models of overt spontaneous breast cancer metastasis: A cautionary note

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Paez Ribes, Marta ^a   Man, Shan ^a   Xu, Ping ^a   Kerbel, Robert S ^a,b  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFESPAN; LUNG METASTASIS; MOUSE; NONHUMAN; OVERT SPONTANEOUS BREAST CANCER METASTASIS; PATIENT TUMOR TISSUE DERIVED XENOGRAFT; SCID MOUSE; SURVIVAL TIME; THYMUS LYMPHOMA; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR REGROWTH; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DISEASE MODEL; METASTASIS; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PHENOTYPE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84977633044     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0158034     Document Type: Article

References (37)

1. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006; 66(7):3386-91. Epub 2006/04/06. 66/7/3386 [pii] doi: 10.1158/0008-5472.CAN-05-4411 PMID: 16585158.
2. Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res. 2008; 68(12):4500-5. Epub 2008/06/19. 68/12/4500 [pii] doi: 10.1158/0008-5472.CAN-08-0041 PMID: 18559492.
3. Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol Cancer Ther. 2010; 9(4):996-1006. Epub 2010/04/08. 1535-7163.MCT-09-0960 [pii] doi: 10.1158/1535-7163.MCT-09-0960 PMID: 20371722; PubMed Central PMCID: PMC2852477.
4. Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 2013; 62(2):259-71. Epub 2012/05/01. gutjnl-2011-301585 [pii] doi: 10.1136/gutjnl-2011-301585 PMID: 22543158; PubMed Central PMCID: PMC3553490.
5. Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med. 2015; 7(282):282ra50. Epub 2015/04/10. 7/282/282ra50 [pii] doi: 10.1126/scitranslmed.3010722 PMID: 25855496.
6. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011; 11(2):135-41. Epub 2011/01/25. nrc3001 [pii] doi: 10.1038/nrc3001 PMID: 21258397.
7. Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 2013; 73(9):2743-8. Epub 2013/04/24. 0008-5472.CAN-12-4183 [pii] doi: 10.1158/0008-5472.CAN-12-4183 PMID: 23610448; PubMed Central PMCID: PMC4334448.
8. Barrios CH, Liu MC, Lee SC, Vanlemmens L, Ferrero JM, Tabei T, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010; 121(1):121-31. Epub 2010/03/27. doi: 10.1007/s10549-010-0788-0 PMID: 20339913; PubMed Central PMCID: PMC2855860.
9. Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol. 2012; 30(9):921-9. Epub 2012/02/15. JCO.2011.35.7376 [pii] doi: 10.1200/JCO.2011.35.7376 PMID: 22331954.
10. Crown JP, Dieras V, Staroslawska E, Yardley DA, Bachelot T, Davidson N, et al. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol. 2013; 31(23):2870-8. Epub 2013/07/17. JCO.2012.43.3391 [pii] doi: 10.1200/JCO.2012.43.3391 PMID: 23857972.
11. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. Epub 2007/12/28. 357/26/2666 [pii] doi: 10.1056/NEJMoa072113 PMID: 18160686.
12. Kerbel RS, Grothey A. Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. Nat Rev Clin Oncol. 2015. Epub 2015/05/13. nrclinonc.2015.89 [pii] doi: 10.1038/nrclinonc.2015.89 PMID: 25963090.
13. Simkens LH, van Tinteren H, May A, Ten Tije AJ, Creemers GJ, Loosveld OJ, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015. Epub 2015/04/12. S0140-6736(14)62004-3 [pii] doi: 10.1016/S0140-6736(14)62004-3 PMID: 25862517.
14. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. Epub 2012/04/18. nrclinonc.2012.61 [pii] doi: 10.1038/nrclinonc.2012.61 PMID: 22508028; PubMed Central PMCID: PMC3928688.
15. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011; 17(11):1514-20. Epub 2011/10/25. nm.2454 [pii] doi: 10.1038/nm.2454 PMID: 22019887; PubMed Central PMCID: PMC3553601.
16. Tait LR, Pauley RJ, Santner SJ, Heppner GH, Heng HH, Rak JW, et al. Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer. 2007; 120(10):2127-34. Epub 2007/02/03. doi: 10.1002/ijc.22572 PMID: 17266026.
17. Custer RP, Bosma GC, Bosma MJ. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol. 1985; 120(3):464-77. Epub 1985/09/01. PMID: 2412448; PubMed Central PMCID: PMC1887984.
18. Kato C, Fujii E, Chen YJ, Endaya BB, Matsubara K, Suzuki M, et al. Spontaneous thymic lymphomas in the non-obese diabetic/Shi-scid, IL-2R gamma (null) mouse. Lab Anim. 2009; 43(4):402-4. Epub 2009/06/10. la.2009.009012 [pii] doi: 10.1258/la.2009.009012 PMID: 19505936.
19. Prochazka M, Gaskins HR, Shultz LD, Leiter EH. The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency. Proc Natl Acad Sci U S A. 1992; 89(8):3290-4. Epub 1992/04/15. PMID: 1373493; PubMed Central PMCID: PMC48852.
20. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999; 17(4):343-59. Epub 2000/04/12. PMID: 10759402.
21. Hoffman RM. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer. 2015:451-2. doi: 10.1038/nrc3972 PMID: 26422835
22. Furukawa T, Kubota T, Watanabe M, Kitajima M, Hoffman RM. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice: correlation of metastatic sites in mouse and individual patient donors. Int J Cancer. 1993; 53(4):608-12. Epub 1993/02/20. PMID: 8436434.
23. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A. 1992; 89(12):5645-9. Epub 1992/06/15. PMID: 1608975; PubMed Central PMCID: PMC49349.
24. Hiroshima Y, Zhang Y, Zhang N, Maawy A, Mii S, Yamamoto M, et al. Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. PLoS One. 2015; 10(2):e0117417. Epub 2015/02/18. doi: 10.1371/journal.pone.0117417 PONE-D-14-37745 [pii]. PMID: 25689852; PubMed Central PMCID: PMC4331082.
25. An Z, Jiang P, Wang X, Moossa AR, Hoffman RM. Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection. Clin Exp Metastasis. 1999; 17(3):265-70. Epub 1999/08/04. PMID: 10432012.
26. Fu XY, Besterman JM, Monosov A, Hoffman RM. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A. 1991; 88(20):9345-9. Epub 1991/10/15. PMID: 1924398; PubMed Central PMCID: PMC52711.
27. Wang X, Fu X, Kubota T, Hoffman RM. A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in nude mice. Anticancer Res. 1992; 12(5):1403-6. Epub 1992/09/01. PMID: 1332576.
28. Fu X, Le P, Hoffman RM. A metastatic orthotopic-transplant nude-mouse model of human patient breast cancer. Anticancer Res. 1993; 13(4):901-4. Epub 1993/07/01. PMID: 8352558.
29. Bayoumi Y, AbdelSamie A, Abdelsaid A, Radwan A. Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy. Breast Cancer (Dove Med Press). 2014; 6:151-8. Epub 2014/09/18. doi: 10.2147/BCTT.S69309 bctt-6-151[pii]. PMID: 25228818; PubMed Central PMCID: PMC4164153.
30. Dominici LS, Mittendorf EA, Wang X, Liu J, Kuerer HM, Hunt KK, et al. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy. Breast Cancer Res. 2012; 14(3):R82. Epub 2012/05/25. bcr3197 [pii] doi: 10.1186/bcr3197 PMID: 22621306; PubMed Central PMCID: PMC3446345.
31. Millar EK, Graham PH, O'Toole SA, McNeil CM, Browne L, Morey AL, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009; 27(28):4701-8. Epub 2009/09/02. JCO.2008.21.7075 [pii] doi: 10.1200/JCO.2008.21.7075 PMID: 19720911.
32. Milsom CC, Lee CR, Hackl C, Man S, Kerbel RS. Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rgamma(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. PLoS One. 2013; 8(8): e71270. Epub 2013/08/24. doi: 10.1371/journal.pone.0071270 PONE-D-13-26548 [pii]. PMID: 23967178; PubMed Central PMCID: PMC3743873.
33. Adelaye-Ogala RM SL, Chintala S. Anti-tumor and anti-metastatic effect of sunitinib in patient derived metastatic clear cell renal cell carcinoma xenograft model. AACR Annual Meeting2015.
34. Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015; 21(7):751-9. Epub 2015/06/23. nm.3886 [pii] doi: 10.1038/nm.3886 PMID: 26099045; PubMed Central PMCID: PMC4500826.
35. Waghorne C, Thomas M, Lagarde A, Kerbel RS, Breitman ML. Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. Cancer Res. 1988; 48(21):6109-14. Epub 1988/11/01. PMID: 3167857.
36. Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res. 1990.
37. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-77. Epub 2015/09/28. 2159-8290.CD-15-0369 [pii] doi: 10.1158/2159-8290.CD-15-0369 PMID: 26410082.